IL-4 induces immune deviation from TH1 to TH2 responses, which prevents tumor rejection [137]; IL-10 suppresses the anti-tumor immunity and contributes to tumor immune escape [135] and IL-13 compromises the anti-tumor response by inhibiting IFN-γ secretion and CD8+ T lymphocyte activity [138]. This evidence concerns the gene IL13 and neoplasm.